Core Viewpoint - Enwei Pharmaceutical reported a revenue of 188 million yuan for Q3 2025, representing an increase of 8.97% year-on-year, but incurred a net loss of 1.76 million yuan due to production line upgrades and increased marketing expenses [1] Group 1 - The company achieved a revenue of 188 million yuan in Q3 2025, which is an 8.97% increase compared to the same period last year [1] - The net profit for the quarter was a loss of 1.76 million yuan, primarily due to the impact of technical upgrades on the core product production line and rapid expansion of the e-commerce division [1] - The production line upgrade for the core product, Jieryin Wash, affected the shipment progress of certain product specifications, but the construction was nearly completed by the end of Q3, allowing for recovery in production and shipping [1]
恩威医药：2025年第三季度实现营收1.88亿元，同比增加8.97%